Molecule Information

General Information of the Molecule (ID: Mol01782)

Name	hsa_circ_BA9.3 ,Homo sapiens
Molecule Type	Circular RNA
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s)

3 drug(s) in total

Click to Show/Hide the Full List of Drugs

Dasatinib

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Chronic myeloid leukemia [ICD-11: 2A20.0]				[1]
Resistant Disease	Chronic myeloid leukemia [ICD-11: 2A20.0]			Disease Info
Resistant Drug	Dasatinib			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Inhibition	hsa04210
	Cell proliferation		Activation	hsa05200
In Vitro Model	K562 cells	Blood	Homo sapiens (Human)	CVCL_0004
	Ku812 cells	Bone marrow	Homo sapiens (Human)	CVCL_0379
Experiment for Molecule Alteration	qRT-PCR
Experiment for Drug Resistance	CCk reagent assay; Flow cytometry assay
Mechanism Description	CircBA9.3 promoted cell proliferation and reduced the sensitivity of leukaemic cells to TkIs through up-regulation of the ABL1 and BCR-ABL1 protein expression levels.

Imatinib

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Chronic myeloid leukemia [ICD-11: 2A20.0]				[1]
Resistant Disease	Chronic myeloid leukemia [ICD-11: 2A20.0]			Disease Info
Resistant Drug	Imatinib			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Identified from the Human Clinical Data
Cell Pathway Regulation	Cell apoptosis		Inhibition	hsa04210
	Cell proliferation		Activation	hsa05200
In Vitro Model	K562 cells	Blood	Homo sapiens (Human)	CVCL_0004
	Ku812 cells	Bone marrow	Homo sapiens (Human)	CVCL_0379
Experiment for Molecule Alteration	qRT-PCR
Experiment for Drug Resistance	CCk reagent assay; Flow cytometry assay
Mechanism Description	CircBA9.3 promoted cell proliferation and reduced the sensitivity of leukaemic cells to TkIs through up-regulation of the ABL1 and BCR-ABL1 protein expression levels.

Nilotinib

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Chronic myeloid leukemia [ICD-11: 2A20.0]				[1]
Resistant Disease	Chronic myeloid leukemia [ICD-11: 2A20.0]			Disease Info
Resistant Drug	Nilotinib			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Inhibition	hsa04210
	Cell proliferation		Activation	hsa05200
In Vitro Model	K562 cells	Blood	Homo sapiens (Human)	CVCL_0004
	Ku812 cells	Bone marrow	Homo sapiens (Human)	CVCL_0379
Experiment for Molecule Alteration	qRT-PCR
Experiment for Drug Resistance	CCk reagent assay; Flow cytometry assay
Mechanism Description	CircBA9.3 promoted cell proliferation and reduced the sensitivity of leukaemic cells to TkIs through up-regulation of the ABL1 and BCR-ABL1 protein expression levels.

References

Ref 1	CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis. 2018 Nov;73:38-44. doi: 10.1016/j.bcmd.2018.09.002. Epub 2018 Sep 14.